Strategies of Radioiodine Ablation in Patients with Low-Risk Thyroid Cancer

2012686 citationsJournal Articlebronze Open Access

Authors

Martin Schlumberger · Institut Gustave Roussy

Bogdan Catargi · Centre Hospitalier Universitaire de Bordeaux

Isabelle Borget · Institut Gustave Roussy

Désirèe Deandreis · Institut Gustave Roussy

Slimane Zerdoud · Institut Claudius Regaud

B. Bridji · Centre Hospitalier René-Dubos

Stéphane Bardet

Abstract

The use of recombinant human thyrotropin and low-dose (1.1 GBq) postoperative radioiodine ablation may be sufficient for the management of low-risk thyroid cancer. (Funded by the French National Cancer Institute [INCa] and the French Ministry of Health; ClinicalTrials.gov number, NCT00435851; INCa number, RECF0447.).

Topics & Keywords

Thyroid Cancer Diagnosis and Treatment Thyroid and Parathyroid Surgery Radiation Dose and Imaging

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 366, Issue 18, pp. 1663-1673

DOI: 10.1056/nejmoa1108586

Field-Weighted Citation Impact: 44.76